Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE) presents sleep data from an open-label Phase 2 trial evaluating Zygel for developmental & epileptic encephalopathies (DEE) and autism spectrum disorder (ASD).
Results were presented at the Associated Professional Sleep Societies SLEEP 2021 Annual Meeting.
The treatment was associated with improved sleep in children with clinically significant sleep disorders at baseline.
Furthermore, the children with both DEE and autism spectrum disorder (ASD) showed more wide-ranging sleep benefits than those with DEE alone.
In patients with ASD (n=5), improvements compared to baseline were observed over the 26-week study period in sleep breathing, sleep-wake transition, and the total sleep disturbance scale for children.
In patients without ASD (n=11), improvement was seen in initiating and maintaining sleep.
Zygel was well tolerated. Most treatment-emergent adverse events were characterized as mild or moderate.
Over the 26-week study period, 60.4% of participants had more than one related adverse event, with 93% mild/moderate severity.
Price Action: ZYNE shares are up 2.95% at $5.58 during the market session on the last check Friday.
See more from Benzinga
© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.